Table: Anges -Q1 group results
May 10 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2022 Mar 31, 2021 Dec 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 15 mln 11 mln
(+33.3 pct) (+101.4 pct)
Operating loss 3.54 loss 3.63
Recurring loss 2.93 loss 3.36
Net loss 2.94 loss 3.31
EPS loss 19.20 yen loss 24.82 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001